Comparative Evaluation of Safety of Different Schemes of Antiplatelet Therapy
Introduction. The need for long-term use of antiplatelet for prevention of cardiovascular complications has long been standardized in a number of guidelines for the treatment of cardiovascular disease. Today, much attention is paid to safety of different formulations. Taking into account an interest to this problem, we have made a direct comparison of the various forms of acetylsalicylic acid (ASA) — enteric-coated ASA (Polocard) and combined drug of ASA and magnesium hydroxide.
Materials and Methods. We have observed 48 patients with ischemic heart disease (stable angina), men aged 45.2 ± 1.8 years, who received antiplatelet therapy. Patients in both groups were comparable in age and presence of comorbidities. Based on these data, it was determined that both of the studied drugs cause adverse reactions, which are clinically manifested by various symptoms of dyspepsia and changes in the structure of the mucous membrane of the stomach revealed by fibrogastroduodenoscopy (FGDS). However, the number of patients, complaining of nausea, heartburn and epigastric pain, was lower in Polocard group than in patients treated with combined drug of ASA and magnesium hydroxide. In carrying out FGDS it was found that hyperemia of the mucous membrane of the stomach has been detected in 48 % of patients, administered with combined drug of ASA and magnesium hydroxide, and erosions were diagnosed in 28 % of patients compared to 26 and 17.4 % respectively in Polocard group. It was found that the safety of enteric-coated drug in higher than safety of ASA in combination with magnesium hydroxide.
Full Text:PDF (Русский)
Горбась И.М. Ішемічна хвороба серця: епідеміологія і статистика // Здоров’я України. — 2009. — № 14/1. — С. 34-35.
Горбась М.М. Епідеміологічна ситуація щодо серцево-судинних захворювань в Україні: 30-річне моніторування // Практическая ангиология. — 2011. — № 7–8(46).
Коваленко В.М., Корнацький В.М. Регіональні особливості рівня здоров’я народу України. Аналітично-статистичний посібник. — К., 2011. — С. 45.
Berger J. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis / J. Berger, D. Brown, R. Becker // Am. J. Med. — 2006. — Vol. 121, № 1. — Р. 43-49.
Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients // B.M.J. — 2002. — Vol. 324. — Р. 71-86.
Baigent C., Blackwell L., Collins R. et al. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials // Lancet. — 2009. — V. 373(9678). — Р. 1849-60.
Jonsson B., Hansson L., Stalhammar N.O. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension // J. Intern. Med. — 2003. — Vol. 253. — P. 472-480.
Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care / Rodriguez L.A., Cea-Soriano L., Martin-Merino E., Johansson S. // B.M.J. — 2011. — V. 343, № d 4094. — doi: 10.1136/bmj.d4094.
Лагута П.С., Панченко Е.П. Применение Аспирина у кардиологических больных // Consilium Medicum. — 2007. — № 15.
Copyright (c) 2016 HYPERTENSION
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018